Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
Recruiting
Observational Study
Inflammatory Disease
Drug Side Effect
Drug Use
Adverse Drug Event
Adverse Drug Reaction
Safety Issues
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 150 (estimated)
- Sponsor
- Universidade do Porto · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \& Co. KG.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Prescription of Rinvoq™ from January 1, 2024;
* 18 years of age or older at the time of recruitment; and
* Expressed consent to participate in the study.
Exclusion Criteria:
* They have any degree of cognitive impairment that prevents them from responding to a questionnaire …
Contacts